Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells
- 12 March 2010
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 125 (1) , 55-63
Abstract
Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.Keywords
This publication has 32 references indexed in Scilit:
- Rational Combinations Using HDAC InhibitorsClinical Cancer Research, 2009
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium StudyClinical Cancer Research, 2008
- Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patientsAnnals of Oncology, 2008
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?British Journal of Cancer, 2008
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaClinical Cancer Research, 2008
- Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinomaLaboratory Investigation, 2008
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast CancerThe Oncologist, 2005